Skip to main content

Search Videos and More

Showing 1 - 10 of 10 results

Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor

Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

FDA Approves New Therapy for Glioma Patients for First Time in Decades

FDA Approves New Therapy for Glioma Patients for First Time in Decades

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.

New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines

New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines

In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.

Study Provides New Look at why Rare Cancer Often Evades Treatments

Study Provides New Look at why Rare Cancer Often Evades Treatments

Researchers at Dana-Farber Cancer Institute and Boston Medical Center conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single cell resolution, unlocking new insights into this rare and often hard-to-treat cancer.

Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma

Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology.

FDA Approves New Treatment Option For Glioma

FDA Approves New Treatment Option For Glioma

The U.S. Food and Drug Administration’s accelerated approval of a two-drug therapy for solid tumors carrying a specific mutation in the BRAF gene is a prime example of this trend. For patients with glioma brain cancer that harbors the mutation, the ruling is a landmark.

Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma

Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma

Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Targeted Drug Combination Shows Unprecedented Activity in Some Highly Aggressive Brain Tumors

Targeted Drug Combination Shows Unprecedented Activity in Some Highly Aggressive Brain Tumors

Treatment with dabrafenib and trametinib yielded encouraging rate of durable responses in both high-grade and low-grade brain tumors carrying the rare BRAF v600E mutation. Study is first to show benefit of any targeted drugs in glioblastomas – the most aggressive brain tumor.

New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain Cancer

New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain Cancer

Researchers at Dana-Farber Cancer Institute and MIT have developed a new way to determine whether individual patients will respond to a specific cancer drug or not.

New Immunotherapy Target Discovered for Malignant Brain Tumors

New Immunotherapy Target Discovered for Malignant Brain Tumors

Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system.